Lung Transplant; Complications

1
Pipeline Programs
2
Companies
3
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Veloxis Pharmaceuticals
1 program
1
Tacrolimus Extended Release Oral Tablet [Envarsus]Phase 11 trial
Active Trials
NCT04469842RecruitingEst. Dec 2026
Abbott
AbbottABBOTT PARK, IL
1 program
Ensure EnliveN/A2 trials
Active Trials
NCT04522388Terminated2Est. Jan 2024
NCT03529019Recruiting30Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Veloxis PharmaceuticalsTacrolimus Extended Release Oral Tablet [Envarsus]
AbbottEnsure Enlive
AbbottEnsure Enlive

Clinical Trials (3)

Total enrollment: 32 patients across 3 trials

NCT04469842Veloxis PharmaceuticalsTacrolimus Extended Release Oral Tablet [Envarsus]

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

Start: Dec 2023Est. completion: Dec 2026
Phase 1Recruiting
NCT03529019AbbottEnsure Enlive

Nutrition in Patient With Critical Limb Ischemia

Start: Oct 2018Est. completion: Jun 202630 patients
Phase 1Recruiting
NCT04522388AbbottEnsure Enlive

Examining the Effect of Nutritional Supplementation on Skeletal Muscle Mass in Patients Awaiting Lung Transplant

Start: Sep 2023Est. completion: Jan 20242 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 32 patients
2 companies competing in this space